Rajeev Kumar, MD

home / authors / rajeev-kumar-md

Articles

Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

Rajeev Kumar, MD
April 23rd 2023

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

Treating OFF Episodes in Parkinson’s Disease During COVID-19

Treating OFF Episodes in Parkinson’s Disease During COVID-19

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Device-Assisted and Surgical Options for Advanced Motor Fluctuations in Parkinson’s Disease

Device-Assisted and Surgical Options for Advanced Motor Fluctuations in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Recently Approved Oral Therapies for OFF Episodes in Parkinson’s Disease

Recently Approved Oral Therapies for OFF Episodes in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Levodopa Inhalation Powder for OFF Episodes in Parkinson’s Disease

Levodopa Inhalation Powder for OFF Episodes in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Continuous Subcutaneous Apomorphine Infusion in Development for OFF Episodes in Parkinson’s Disease

Continuous Subcutaneous Apomorphine Infusion in Development for OFF Episodes in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Recent Approval of Sublingual Apomorphine for Off-Episodes in Parkinson Disease

Recent Approval of Sublingual Apomorphine for Off-Episodes in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Apomorphine Subcutaneous Injection: Circle of Care Program for Off-Episodes in Parkinson Disease

Apomorphine Subcutaneous Injection: Circle of Care Program for Off-Episodes in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Apomorphine Subcutaneous Injection: Patient Selection for Off-Episodes in Parkinson Disease

Apomorphine Subcutaneous Injection: Patient Selection for Off-Episodes in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Apomorphine Subcutaneous Injection: Efficacy and Administration for Off-Episodes in Parkinson Disease

Apomorphine Subcutaneous Injection: Efficacy and Administration for Off-Episodes in Parkinson Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Apomorphine Subcutaneous Injection: Historical Perspective for Off-Episodes in Parkinson’s Disease

Apomorphine Subcutaneous Injection: Historical Perspective for Off-Episodes in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020
Overview of OFF Episodes in Parkinson’s Disease

Overview of OFF Episodes in Parkinson’s Disease

Daniel E. Kremens, MD, JD;Rajeev Kumar, MD
October 13th 2020

Latest Updated Articles

FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Published: January 30th 2025 | Updated: February 21st 2025
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
Published: February 15th 2025 | Updated: February 18th 2025
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
Published: February 4th 2025 | Updated: February 6th 2025
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
Published: January 30th 2025 | Updated: February 4th 2025
FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment
© 2025 MJH Life Sciences

All rights reserved.